Delivering a normal GBA1 gene using an adeno-associated virus (AAV) vector to a variety of animal models of PD or PD-GBA, including various genetic models with α-synuclein or GBA1 gene mutations, has been shown to be efficacious by multiple independent investigators [37–41]. This evidence concerns the gene GBA1 and Parkinson disease.